News
03-12-2012, 06:50 AM
InflammaGen Therapeutics, a development-stage, critical care company initially focused on the diagnosis, treatment and prevention of multi-organ failure (MOF), announced today that the Company has initiated a 200-patient Phase 2 pilot study to examine the efficacy and safety of InflammaGen Shok-Pak as a potential treatment for critically ill patients in the Intensive Care Unit.
More... (http://www.news-medical.net/news/20120312/InflammaGen-Therapeutics-initiates-Shok-Pak-Phase-2-pilot-study.aspx)
More... (http://www.news-medical.net/news/20120312/InflammaGen-Therapeutics-initiates-Shok-Pak-Phase-2-pilot-study.aspx)